The Journal of Urology
Volume 182, Issue 1 , Pages 125-132, July 2009

Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy

  • Michael J. Donovan

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Corresponding Author InformationCorrespondence: Aureon Laboratories, Inc., 28 Wells Ave., Yonkers, New York 10701 (telephone: 914-377-4037; FAX: 914-377-4001)
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Faisal M. Khan

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Gerardo Fernandez

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Ricardo Mesa-Tejada

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Marina Sapir

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Valentina Bayer Zubek

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Douglas Powell

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Stephen Fogarasi

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Yevgen Vengrenyuk

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Mikhail Teverovskiy

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Mark R. Segal

      Affiliations

    • Center for Bioinformatics and Molecular Biostatistics, University of California-San Francisco, San Francisco, California
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • R. Jeffrey Karnes

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • Thomas A. Gaffey

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • Christer Busch

      Affiliations

    • University Hospital at Uppsala, Uppsala, Sweden
    • ,
  • Michael Haggman

      Affiliations

    • University Hospital at Uppsala, Uppsala, Sweden
    • ,
  • Peter Hlavcak

      Affiliations

    • University Hospital at Uppsala, Uppsala, Sweden
    • ,
  • Stephen J. Freedland

      Affiliations

    • Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Robin T. Vollmer

      Affiliations

    • Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina
    • ,
  • Peter Albertsen

      Affiliations

    • University of Connecticut Health Science Center, Farmington, Connecticut
    • Financial interest and/or other relationship with Sanofi, Bristol Meyers, Galaxo and Blue Cross Blue Shield.
    • ,
  • Jose Costa

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Yale University School of Medicine, New Haven, Connecticut
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Carlos Cordon-Cardo

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.

Received 18 December 2008 published online 18 May 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Study received Durham Veterans Affairs Medical Center, Mayo Clinic, University of Connecticut Health Science Center, University of Graz and University Hospital at Uppsala institutional review board approval.

 Supported by an Aureon Laboratories sponsored research agreement.

 Supplementary material for this article can be obtained at jason.alter@aureon.com.

 For another article on a related topic see page 317.

PII: S0022-5347(09)00570-9

doi:10.1016/j.juro.2009.02.135

Refers to article:

  • Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer , 18 May 2009

    Ulka N. Vaishampayan, Shanthi Marur, Lance K. Heilbrun, Michael L. Cher, Brenda Dickow, Daryn W. Smith, Samir A. Al Hasan, James Eliason
    The Journal of Urology July 2009 (Vol. 182, Issue 1, Pages 317-323)

The Journal of Urology
Volume 182, Issue 1 , Pages 125-132, July 2009

Article Tools

* Image Usage & Resolution